Sulfanitran

Sulfanitran

SCHEMBL93837

CC(=O)Nc1ccc(S(=O)(=O)Nc2ccc([N+](=O)[O-])cc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 1.00
ALDH1A1 P00352 7/20 1.00
MEN1 O00255 6/20 1.00
KDM4E B2RXH2 1/20 1.00
CYP3A4 P08684 1/20 1.00
HPGD P15428 1/20 1.00
TDP1 Q9NUW8 1/20 1.00
GAA P10253 3/20 0.68
HSP90AA1 P07900 1/20 0.65
CA2 P00918 2/20 0.64
CA1 P00915 1/20 0.64
MAPK1 P28482 1/20 0.63
GFER P55789 1/20 0.63
CA12 O43570 1/20 0.63
CA9 Q16790 1/20 0.63
MAPT P10636 2/20 0.62
LMNA P02545 1/20 0.62
ALOX12 P18054 1/20 0.62
KDM1A O60341 1/20 0.62
THRB P10828 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfanitran SCHEMBL7173413 0.88 ALDH1A1 (0.77) KMT2AALDH1A1MEN1KDM4ECYP3A4
SCHEMBL3891683 0.86 KMT2A (1.00) KMT2AALDH1A1MEN1KDM4ECYP3A4
SCHEMBL16922176 0.86 KMT2A (0.81) KMT2AALDH1A1MEN1KDM4ECYP3A4
SCHEMBL642700 0.86 KMT2A (0.81) KMT2AALDH1A1MEN1KDM4ECYP3A4
SCHEMBL7498033 0.86 CA2 (0.83) KMT2AALDH1A1MEN1KDM4ECYP3A4
SCHEMBL4896083 0.85 MEN1 (0.74) KMT2AALDH1A1MEN1KDM4ECYP3A4
Phosphine SCHEMBL28320532 0.84 KMT2A (0.78) KMT2AALDH1A1MEN1KDM4ECYP3A4
SCHEMBL4730843 0.83 KMT2A (0.70) KMT2AALDH1A1MEN1KDM4ECYP3A4
SCHEMBL11442412 0.81 CA2 (0.71) KMT2AALDH1A1MEN1KDM4ECYP3A4
SCHEMBL9365750 0.81 PKM (0.73) KMT2AALDH1A1MEN1KDM4ECYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2235 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120161031-A Method for rapidly identifying malathion based on fluorescent nano probe 百色学院 2025-06-17 CN claimed
EP-4552693-A2 COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND DEVICES AND METHODS OF PRODUCTION AND USE THEREOF Sustain Holdings, LLC (US) 2025-05-14 EP claimed
WO-2025080590-A1 CO-CRYSTALLIZATION OF ACTIVES WITH SACCHARIDE-BASED MOLECULAR FRAMEWORKS SCIENTIFIC HORIZONS CONSULTING LLC (US) 2025-04-17 WO claimed
US-20250099557-A1 ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION SHANGHAI BAO PHARMACEUTICALS CO., LTD. (CN) 2025-03-27 US claimed
EP-3958889-B1 COLLAGEN MIMETIC PEPTIDE COMPOSITIONS FOR TREATING A POSTERIOR SEGMENT OCULAR DISEASE OR DISORDER INVOLVING THE RETINA, RETINAL BLOOD VESSELS, RETINAL NERVES OR OPTIC NERVE SUSTAIN HOLDINGS LLC (US) 2025-01-08 EP claimed
US-20250006331-A1 QUANTITATIVE SYSTEMS PHARMACOLOGY METHODS FOR IDENTIFYING THERAPEUTICS FOR DISEASE STATES UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) 2025-01-02 US claimed
EP-4374848-A1 ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION Shanghai Bao Pharmaceuticals Co., Ltd. (CN) 2024-05-29 EP claimed
US-20240065979-A1 Protection of Polyunsaturated Fatty Acids, Lipid-Soluble Vitamins, and Lipid-Soluble Medicaments from Oxidation One Idea LLC (US) 2024-02-29 US claimed
EP-4271371-A1 PROTECTION OF POLYUNSATURATED FATTY ACIDS, LIPID-SOLUBLE VITAMINS, AND LIPID-SOLUBLE MEDICAMENTS FROM OXIDATION One Idea LLC (US) 2023-11-08 EP claimed
EP-4237445-A2 COMPOSITIONS AND METHODS FOR PREVENTING, INHIBITING, DISRUPTING, OR TREATING A POLYMICROBIAL BIOFILM Research Institute at Nationwide Children's Hospital (US) 2023-09-06 EP claimed
EP-0786999-A1 COMBINATION METHOD FOR ACNE TREATMENT Merck & Co., Inc. (US) 1997-08-06 EP claimed
EP-0741570-A1 METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS G.D. SEARLE & CO. (US) 1996-11-13 EP claimed
US-5543417-A 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent MERCK & CO., INC. (US) 1996-08-06 US claimed
WO-1996012817-A1 COMBINATION METHOD FOR ACNE TREATMENT MERCK & CO., INC. (US) 1996-05-02 WO claimed
WO-1996012487-A1 COMBINATION METHOD FOR ACNE TREATMENT MERCK & CO., INC. (US) 1996-05-02 WO claimed
WO-1995020387-A1 METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS G.D. SEARLE & CO. (US) 1995-08-03 WO claimed
EP-0572560-A4 USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY. SHAPIRO HOWARD K (US) 1995-04-26 EP claimed
EP-0572560-A1 USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY SHAPIRO, Howard, K. (US) 1993-12-08 EP claimed
WO-1992014456-A1 USE OF PHARMACEUTICAL COMPOUNDS IN THE TREATMENT OF SYMPTOMS OF DISORDERS RELATED TO NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY SHAPIRO HOWARD K (US) 1992-09-03 WO claimed
US-4094976-A ANTICOCCIDIAL CYCLICAMINO ETHANOLS AND ESTERS THEREOF MERCK & CO., INC. (US) 1978-06-13 US claimed